SEC Company Response from ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514) (ADMA) — Apr 30, 2013
ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514)
Date: April 30, 2013 · CIK: 0001368514 · Accession: 0001193805-13-000859
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-186579
Letter
Re:
Unassociated Document
April 30, 2013
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
ADMA Biologics, Inc.
Registration Statement on Form S-1, as amended
File No. 333-186579
Ladies and Gentlemen:
In connection with the above-captioned Registration Statement, we wish to advise you that as of the date hereof, approximately 1,300 copies of the Preliminary Prospectus dated April 30, 2013 were distributed as follows: approximately 0 to prospective underwriters; approximately 300 to institutional investors; approximately 0 to prospective dealers; and approximately 1,000 to individuals.
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.
We hereby join in the request of the registrant that the effectiveness of the above-referenced Registration Statement, as amended, be accelerated to 4:00 pm Eastern time on April 30, 2013 or as soon thereafter as practicable.
Very truly yours,
Oppenheimer & Co. Inc.
Show Raw Text
CORRESP
1
filename1.htm
Unassociated Document
April 30, 2013
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re:
ADMA Biologics, Inc.
Registration Statement on Form S-1, as amended
File No. 333-186579
Ladies and Gentlemen:
In connection with the above-captioned Registration Statement, we wish to advise you that as of the date hereof, approximately 1,300 copies of the Preliminary Prospectus dated April 30, 2013 were distributed as follows: approximately 0 to prospective underwriters; approximately 300 to institutional investors; approximately 0 to prospective dealers; and approximately 1,000 to individuals.
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.
We hereby join in the request of the registrant that the effectiveness of the above-referenced Registration Statement, as amended, be accelerated to 4:00 pm Eastern time on April 30, 2013 or as soon thereafter as practicable.
Very truly yours,
Oppenheimer & Co. Inc.
BMO Capital Markets Corp.
As Representatives of the severalUnderwriters
Oppenheimer & Co. Inc.
By:
/s/ Douglas Cameron
Name: Douglas Cameron
Title: Managing Director
BMO Capital Markets Corp.
By:
/s/ Lori A. Begley
Name: Lori A. Begley
Title: Managing Director